Molecular diagnosis and therapy of kidney cancer

Annual Review of Medicine

Volumn 61, Issue , 2010, Pages 329-343

  Linehan, W Marston ^a   Bratslavsky, Gennady ^a   Pinto, Peter A ^a   Schmidt, Laura S ^a,b   Neckers, Len ^a   Bottaro, Donald P ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

BHD; Fumarate hydratase succinate dehydrogenase; Kidney neoplasms; MET; TSC1; TSC2; VHL

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FORETINIB; FUMARATE HYDRATASE; GENE PRODUCT; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FLCN PROTEIN, HUMAN; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; ONCOPROTEIN; SCATTER FACTOR RECEPTOR; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ADJUVANT THERAPY; ANGIOMYOLIPOMA; ANTIANGIOGENIC ACTIVITY; BIRT HOGG DUBE SYNDROME; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHROMOPHOBE ADENOMA; CHROMOSOME 7; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; CYTOREDUCTIVE SURGERY; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; FATIGUE; GENE IDENTIFICATION; GENE MUTATION; GENETIC LINKAGE; HAND FOOT SYNDROME; HEREDITARY PAPILLARY RENAL CELL CARCINOMA; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEIOMYOMATOSIS; LINKAGE ANALYSIS; MORTALITY; NAUSEA; NEPHRECTOMY; OVERALL SURVIVAL; PAPILLARY CARCINOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR GENE; VON HIPPEL LINDAU DISEASE; CARCINOMA; GENETICS; KIDNEY TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; KIDNEY NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77951923948     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.042808.171650     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E, et al. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59:225-249
2. Chow WH, Devesa SS, Warren JL, et al. 1999. Rising incidence of renal cell cancer in the United States. JAMA 281:1628-1631
3. Linehan WM, Walther MM, Zbar B. 2003. The genetic basis of cancer of the kidney. J. Urol. 170:2163-2172
4. Linehan WM, Bates SE, Yang JC. 2005. Cancer of the kidney. In Cancer: Principles and Practice of Oncology, ed. SE DeVita, S Hellman, SA Rosenberg, pp. 1139-1168 Philadelphia: Lippincott Williams & Wilkins. 7th ed.
5. Walther MM, Lubensky IA, Venzon D, et al. 1995. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154:2010-2014
6. Walther MM, Choyke PL, Glenn G, et al. 1999. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J. Urol. 161:1475-1479
7. Herring JC, Enquist EG, Chernoff A, et al. 2001. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J. Urol. 165:777-781
8. Duffey BG, Choyke PL, Glenn GM, et al. 2004. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J. Urol. 172:63-65
9. Latif F, Tory K, Gnarra JR, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320 (Pubitemid 23231974)
10. Stolle C, Glenn GM, Zbar B, et al. 1998. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12:417-423
11. Gnarra JR, Tory K, Weng Y, et al. 1994. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. 7:85-90
12. Nickerson ML, Jaeger E, Shi Y,et al. 2008. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14:4726-4734
13. Duan DR, Pause A, Burgess WH, et al. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406
14. Pause A, Lee S, Worrell RA, et al. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94:2156-2161
15. Kibel A, Iliopoulos O, DeCaprio JA, et al. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444-1446
16. Stebbins CE, Kaelin WG, Pavletich NP. 1999. Structure of the VHL-elonginC-elonginB complex: implications for VHL tumor suppressor function. Science 284:455-461
17. Kamura T, Koepp DM, Conrad MN, et al. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661
18. Maxwell PH, Wiesener MS, Chang GW,etal. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
19. 2-regulated prolyl hydroxylation. Science 292:468-472
20. Ohh M, Takagi Y, Aso T, et al. 1999. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Invest. 104:1583-1591
21. Ohh M, Park CW, Ivan M, et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423-427
22. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-vascular en-dothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-434
23. Wilhelm SM, Adnane L, Newell P, et al. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther.7:3129-3140
24. Escudier B, Eisen T, Stadler WM, et al. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356:125-134
25. Escudier B, Eisen T, Stadler WM, etal. 2009. Sorafenib for treatment of renal cell carcinoma:final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J. Clin. Oncol. 27:3312-3318
26. Mendel DB, Laird AD, Xin X, et al. 2003. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9:327-337
27. Motzer RJ, Hutson TE, Tomczak P, et al. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356:115-124
28. RixeO, Bukowski RM, Michaelson MD, etal. 2007. Axitinib treatmentinpatients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 8:975-984
29. Linehan WM. 2007. Targeting VEGF receptors in kidney cancer. Lancet Oncol. 8:956-957
30. Hudson CC, Liu M, Chiang GG, et al. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22:7004-7014
31. Thomas GV, Tran C, Mellinghoff IK, et al. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12:122-127
32. Hudes G, Carducci M, Tomczak P, et al. 2007. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356:2271-2281 (Pubitemid 46849157)
33. Motzer RJ, Escudier B, Oudard S, et al. 2008. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:427-429
34. Feldman DR, Baum MS, Ginsberg MS, et al. 2009. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27:1432-1439
35. Patel PH, Senico PL, Curiel RE, et al. 2009. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 7:24-27
36. Motzer RJ, Hudes G, Wilding G, et al. 2009. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7:28-33
37. Escudier B, Goupil MG, Massard C, et al. 2009. Sequential therapy in renal cell carcinoma. Cancer 115:2321-2326
38. Walther MM, Alexander RB, Weiss GI, et al. 1993. Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urol. 42:250-258
39. Flanigan RC, Salmon SE, Blumenstein BA, et al. 2001. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345:1655-1659
40. Wagner JR, Walther MM, Linehan WM, et al. 1999. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol. 162:43-45
41. van der Veldt AA, Meijerink MR, Van Den Eertwegh AJ, et al. 2008. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14:2431-2436
42. Shuch B, Riggs SB, LaRochelle JC, et al. 2008. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102:692-696
43. Karakiewicz PI, Suardi N, Jeldres C, et al. 2008. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53:845-848
44. Margulis V, Matin SF, Tannir N, et al. 2008. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180:94-98
45. Haas NB, Uzzo R. 2008. Adjuvant therapy for renal cell carcinoma. Curr. Oncol. Rep. 10:245-252
46. Ivanov SV, Kuzmin I, Wei MH, et al. 1998. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 95:12596-12601
47. Kaluz S, Kaluzova M, Liao SY, et al. 2009. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim. Biophys. Acta 1795:162-172
48. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. 1997. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol. 15:1529-1537
49. UemuraH,Nakagawa Y, Yoshida K, et al. 1999. MN/CA IX/G250as apotential target for immunotherapy of renal cell carcinomas. Br. J. Cancer 81:741-746
50. Bui MH, Seligson D, Han KR, et al. 2003. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9:802-811
51. Bui MH, Visapaa H, Seligson D, et al. 2004. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol. 171:2461-2466
52. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. 2007. Preoperative characterization of clear-cell renal carcinoma using iodine-124-labeled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 8:304-310
53. Zbar B, Tory K, Merino MJ, et al. 1994. Hereditary papillary renal cell carcinoma. J. Urol. 151:561-566
54. Schmidt L, Duh FM, Chen F, et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:68-73
55. Schmidt L, Junker K, Weirich G, et al. 1998. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 58:1719-1722
56. Ornstein DK, Lubensky IA, Venzon D, et al. 2000. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J. Urol. 163:431-433
57. Chernoff A, Choyke PL, Linehan WM, et al. 2001. Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. J. Urol. 165:1623-1624
58. Srinivasan R, Choueiri TK, Vaishampayan U, et al. 2008. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J. Clin. Oncol. 26(May 20 Suppl.):5103
59. Zbar B, Alvord WG, Glenn GM, et al. 2002. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol. Biomarkers Prev. 11:393-400
60. Pavlovich CP, Walther MM, Eyler RA, et al. 2002. Renal tumors in the Birt-Hogg-Dubé syndrome. Am. J. Surg. Pathol. 26:1542-1552
61. Nickerson ML, Warren MB, Toro JR, et al. 2002. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2:157-164
62. Schmidt LS, Nickerson ML, Warren MB, et al. 2005. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am. J. Hum. Genet. 76:1023-1033
63. Toro JR, Pautler SE, Stewart L, et al. 2007. Lung cysts, spontaneous pneumothorax and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am. J. Respir. Crit. Care Med. 175:1044-1053
64. Vocke CD, Yang Y, Pavlovich CP, et al. 2005. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J. Natl. Cancer Inst. 97:931-935
65. Baba M, Hong SB, Sharma N, et al. 2006. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. USA 103:15552-15557
66. Hasumi H, Baba M, Hong SB, et al. 2008. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415:60-67
67. Baba M, Furihata M, Hong SB, et al. 2008. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J. Natl. Cancer Inst. 100:140-154
68. Launonen V, Vierimaa O, Kiuru M, et al. 2001. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl. Acad. Sci. USA 98:3387-3482
69. Merino MJ, Torres-Cabala C, Pinto P et al. 2007. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am. J. Surg. Pathol. 31:1578-1585
70. Grubb RLIII, Franks ME, ToroJ,etal. 2007. Hereditary leiomyomatosis and renal cell cancer:asyndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177:2074-2080
71. Tomlinson IP, Alam NA, Rowan AJ, et al. 2002. Germline mutations in FH predispose to domi-nantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30:406-410
72. Toro JR, Nickerson ML, Wei MH, et al. 2003. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73:95-106
73. Wei MH, Toure O, Glenn GM, et al. 2006. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J. Med. Genet. 43:18-27
74. Isaacs JS, Jung YJ, Mole DR, et al. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-153
75. Sudarshan S, Sourbier C, Kong HS, et al. 2009. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1α stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell Biol. 15:4080-4090
76. Neumann HP, Pawlu C, Peczkowska M, et al. 2004. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951
77. Vanharanta S, Buchta M, McWhinney SR, et al. 2004. Early-onset renal cell carcinoma as a novel ex-traparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74:153-159
78. Srirangalingam U, Walker L, Khoo B, et al. 2008. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin. Endocrinol. (Oxf.) 69:587-596
79. Henderson A, Douglas F, Perros P, et al. 2009. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam. Cancer 8:257-260
80. Ricketts C, Woodward ER, Killick P, et al. 2008. Germline SDHB mutations and familial renal cell carcinoma. J. Natl. Cancer Inst. 100:1260-1262
81. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N. Engl. J. Med. 355:1345-1356
82. Seyam RM, Bissada NK, Kattan SA, et al. 2008. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urol. 72:1077-1082
83. Bissler JJ, McCormack FX, Young LR, et al. 2008. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358:140-151
84. Walther MM, Choyke PL, Weiss G, et al. 1995. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J. Urol. 153:913-916
85. Rogers CG, Metwalli A, Blatt AM, et al. 2008. Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J. Urol. 180:2353-2356
86. Rogers CG, Singh A, Blatt AM, et al. 2008. Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur. Urol. 53:514-521
87. Boris R, Proano M, Linehan WM, et al. 2009. Initial experience with robot assisted partial nephrectomy for multiple renal masses. J. Urol. 182(4):1280-1286
88. Gill IS, Kavoussi LR, Lane BR, et al. 2007. Comparison of 1800 laparoscopic and open partial nephrec-tomies for single renal tumors. J. Urol. 178:41-46
89. Huang WC, Elkin EB, Levey AS, et al. 2009. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors\Is there a difference in mortality and cardiovascular outcomes? J. Urol. 181:55-61
90. Jewett MA, Zuniga A. 2008. Renal tumor natural history: the rationale and role for active surveillance. Urol. Clin. North Am. 35:627-634
91. Crispen PL, Viterbo R, Boorjian SA, et al. 2009. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115:2844-2852
92. Linehan WM, Pinto PA, SrinivasanR,etal. 2007. Identificationofthe genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 13:671s-9s
93. Pfaffenroth EC, Linehan WM. 2008. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin. Biol. Ther. 8:779-790
94. Schmidt L, Junker K, Nakaigawa N, et al. 1999. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350